ACADIA Pharma Announces Appointment of Elena Ridloff as SVP, Investor Relations

ACADIA Pharmaceuticals Inc. announced that Elena Ridloff, CFA, has been appointed to the newly created position of Senior Vice President, Investor Relations, leading investor and financial communications activities. She will report to Steve Davis, ACADIA’s President and Chief Executive Officer and serve as a member of the company’s Executive Management Committee.

“We are thrilled to welcome Elena Ridloff to our senior leadership team,” said Mr. Davis. “Elena’s deep knowledge of the healthcare industry, strong relationships with the financial community, and keen understanding of capital markets make her a valuable addition to the team as we continue to advance our development and commercial efforts focused on CNS disorders with high unmet needs.”

Ms. Ridloff joins ACADIA from Alexion Pharmaceuticals, where she was Vice President, Investor Relations reporting to the Chief Financial Officer and serving as a member of the Operating Committee. In building and leading the investor relations function at Alexion, she played a key role in developing and executing the company’s investor relations strategy and outreach to broaden and strengthen the shareholder base. Prior to Alexion, she was Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations counsel to the life sciences industry. Ms. Ridloff was also a Managing Director at Maverick Capital, a hedge fund based in New York, and was responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors.

Ms. Ridloff attended the University of Pennsylvania where she earned a Bachelor of Arts in History and Sociology of Science. She is also a CFA charterholder.